RoslinCT appoints David Bowie to Board of DirectorsMarch 22nd 2019

Find out more

RoslinCT, a leading cell and gene therapy contract manufacturing organisation, is pleased to announce the appointment of David Bowie to the Board of Directors. David has over twenty-eight years of international sales, marketing management and business development experience in the global healthcare sector which led him to the board of the Scottish Government backed Life Science Scotland Industry Leadership Group for some 12 years. David brings a wealth of life science industry experience, locally and globally, to the position.

David commented “I am really looking forward to working with Janet and her team at RoslinCT and adding value from my experiences to bring more commercial focus to this exciting and expanding global business”.

David is currently Chief Commercial Officer for Blackford Analysis, a growing business in the medical imaging software market who recently won a Frost & Sullivan Best Practice Award for Visionary Innovation Leadership. Amongst his experiences, David was a Co-Founder and COO of snap40 (now called Current Health); CEO of Ice Robotics, a successful Scottish-based animal health technology business; VP of Global Sales & Marketing at Aircraft Medical (acquired by Medtronic) and worked for Draeger Medical in various international roles over a ten year period, including 5 years based at its German Headquarters.

Janet Downie, CEO of RoslinCT, said “I am delighted to welcome David to the Board. David ‘s commercial expertise will be a huge benefit to RoslinCT as we continue with our growth and expansion and strengthen our position globally.”.

END

For more information, please contact:

Janet Downie CEO
Tel: +44 (0)131 658 5180
Email: janet.downie@roslinct.com
Web: www.roslinct.com

About RoslinCT

RoslinCT is a leading Contract Development and Manufacturing Organisation (CDMO) offering a range of integrated services from technology transfer, process and assay development through to GMP manufacturing, storage, QP certification and batch release of cell-based therapies for clinical trials.

RoslinCT has a vision to lead the field in cell and gene therapy manufacturing and be the global partner of choice, building success on expert knowledge, progressive partnerships and with drive to deliver life-changing cell-based products to patients in need. This together with a passion for innovation and a flexible and personalised approach enables RoslinCT to engage with leading cell and gene therapy developers and to provide support at every step of the cell therapy development journey.

For more information please visit www.roslinct.com

Inside Media

Get In Touch

NINE Edinburgh BioQuarter, 9 Little France Road
Edinburgh, United Kingdom, EH16 4UX


+44 (0) 131 658 5180